Cargando…
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (89)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
Mesothelin is a tumor differentiation antigen expressed by epithelial tumors, including pancreatic cancer. Currently, mesothelin is being targeted with an antibody-drug conjugate (ADC) consisting of a mesothelin-specific antibody coupled to a highly potent chemotherapeutic drug. Considering the toxi...
Autores principales: | ter Weele, Eva J., van Scheltinga, Anton G.T. Terwisscha, Kosterink, Jos G.W., Pot, Linda, Vedelaar, Silke R., Lamberts, Laetitia E., Williams, Simon P., Hooge, Marjolijn N. Lub-de, de Vries, Elisabeth G.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747211/ https://www.ncbi.nlm.nih.gov/pubmed/26536664 |
Ejemplares similares
-
(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
por: Pool, Martin, et al.
Publicado: (2017) -
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018) -
(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017) -
Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer (89)Zr-imgatuzumab
por: Pool, Martin, et al.
Publicado: (2016) -
Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022)